



ASX ANNOUNCEMENT

20 NOVEMBER 2023

PHASE 1B ADVENT-ACUTE MYELOID LEUKEMIA (AML) CLINICAL TRIAL AT MD ANDERSON WITH CHM 0201 NK CELLS TO BE PRESENTED AT ASH

- The ADVENT-AML Phase 1B clinical trial has been accepted for presentation at the premier hematology meeting, American Society of Hematology (ASH)
- The ADVENT-AML trial will study CHM 0201 (NK cell platform) in combination with standard of care for newly diagnosed Acute Myeloid Leukemia patients
- Abstract will highlight the clinical trial design and objectives for the new Phase 1B clinical trial

Chimeric Therapeutics (ASX:CHM, “Chimeric” or the “Company”), an Australian leader in cell therapy, is pleased to announce that the ADVENT-AML Phase 1B clinical trial abstract was selected for presentation at the 2023 Annual Meeting of the American Society of Hematology (ASH), which is being held December 9-12, 2023 in San Diego, California.

Chimeric is pleased that ASH has accepted the abstract for presentation as it highlights the novel design and objectives of the ADVENT-AML clinical trial, the first clinical trial to evaluate the synergy of CHM 0201 NK cells in combination with the current standard of care of Azacitidine and Venetoclax in Acute Myeloid Leukemia patients.

CHM 0201 is Chimeric’s NK cell platform that published positive Phase 1A clinical data in 2022. In the Phase 1A clinical trial, safety and persistence and expansion of CHM 0201 cells was shown alongside promising efficacy in both solid tumours and blood cancers. Of significant note, one Acute Myeloid Leukemia patient in the Phase 1A clinical trial achieved a Complete Response (CR) to CHM 0201 and has remained in ongoing complete remission for more than two years to date.

The ADVENT-AML clinical trial (clinicaltrials.gov NCT05834244) is being conducted at the University of Texas MD Anderson Cancer Center under the direction of Principal Investigator, Abhishek Maiti MD, Assistant Professor in the Department of Leukemia at MD Anderson. The trial has received FDA IND and MDACC IRB clearance and is scheduled to begin enrollment in late 2023 with only nominal funding from Chimeric.

Details of the abstract presentation are as follows:

ASH Abstract #:	4863
ASH Abstract Title:	Azacitidine, Venetoclax and Allogeneic NK Cells in Newly Diagnosed Acute Myeloid Leukemia (ADVENT-AML): An Investigator-Initiated Multicenter Phase 1B Trial
Session:	704: Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster III Hematology Disease Topics and Pathways
Date:	Monday, December 11, 2023
Time:	6:00 – 8:00 PM



ADVENT-AML PHASE 1B CLINICAL TRIAL BACKGROUND

ADVENT-AML will be the first trial to evaluate the synergy of NK cell therapy in combination with the current standard of care of Azacitidine with Venetoclax (AZA-VEN). As the trial progresses beyond dose confirmation, it will also be the first trial to evaluate cellular therapy in newly diagnosed AML patients.

The ADVENT-AML (clinicaltrials.gov NCT05834244) study is designed to enroll up to 20 subjects with newly diagnosed AML who are not eligible for intensive chemotherapy or allogeneic stem cell transplant, following completion of a dose confirmation cohort assessing the safety of this novel combination treatment in subjects with relapsed or refractory AML.

The study, which has received IND clearance by the FDA and is expected to open to enrollment by year end 2023, will be led by Principal Investigator Abhishek Maiti MD, Assistant Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center.

Acute Myeloid Leukemia (AML) is the most common acute leukemia in adults with a median age at diagnosis between 65-72 years. Despite treatment advances, patients who are not eligible for intensive chemotherapy or allogeneic stem cell transplant patients have limited therapeutic options. Outcomes for these high-risk subgroups are poor with median overall survival (mOS) of 6 to 9 months in the newly diagnosed setting¹ and 2.4 months for patients with relapse or refractory disease². Consequently, novel therapies are urgently needed to improve outcomes for patients with AML.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer, not just delay disease progression.

To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 3 current clinical programs and plans to open additional clinical programs in 2023.

CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed for the treatment of patients with solid tumours. CHM 1101 is currently being studied in a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023.

CHM 2101 (CDH17 CAR T) is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania. Preclinical evidence for CHM 2101 was



published in March 2022 in Nature Cancer demonstrating complete eradication of tumors in 7 types of cancer. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1A clinical trial in gastrointestinal and neuroendocrine tumours.

CHM 0201 (CORE-NK platform) is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, an additional Phase1B clinical trial investigating CHM 0201 in combination with IL2 and Vactosertib is now underway. From the CHM 0201 platform, Chimeric has initiated development of new next generation NK and CAR NK assets.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

CONTACT

Investors

Jennifer Chow

Chief Executive Officer and Managing Director
Chimeric Therapeutics

T: + 1 9087238387

E: jchow@chimerictherapeutics.com

W: www.chimerictherapeutics.com

Paul Hopper

Executive Chairman

Chimeric Therapeutics

T: + 61 406 671 515

E: paulhopper@lifescienceportfolio.com

Media

Matthew Wright

NWR Communications

P: +61 451 896 420

E: matt@nwrcommunications.com.au